ADC Therapeutics Shares Drop Over 50% on Disappointing Phase 3 Trial Data
ADC Therapeutics (ADCT) experienced a significant premarket decline of over 50% after the release of topline data from a confirmatory Phase 3 trial for its lymphoma drug Zynlonta. The results failed to meet expectations, leading to negative market reaction.
Tickers: $ADCT
Topics: ADC Therapeutics Phase 3 trial results stock price drop Zynlonta